Bandres-Ciga, Sara 
ORCID: 0000-0003-0056-1361, Faghri, Faraz ORCID: 0000-0001-5744-8728, Majounie, Elisa, Koretsky, Mathew J ORCID: 0000-0003-4341-3991, Kim, Jeffrey ORCID: 0000-0003-0738-0512, Levine, Kristin S, Leonard, Hampton ORCID: 0000-0003-2390-8110, Makarious, Mary B ORCID: 0000-0002-7978-1051, Iwaki, Hirotaka ORCID: 0000-0002-8982-7885, Crea, Peter Wild ORCID: 0000-0001-8944-5716 et al (show 24 more authors)
(2023)
NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations.
medRxiv, 4 (11-20).
2023.11.06.23298176-.
Abstract
Genome-wide genotyping platforms have the capacity to capture genetic variation across different populations, but there have been disparities in the representation of population-dependent genetic diversity. The motivation for pursuing this endeavor was to create a comprehensive genome-wide array capable of encompassing a wide range of neuro-specific content for the Global Parkinson's Genetics Program (GP2) and the Center for Alzheimer's and Related Dementias (CARD). CARD aims to increase diversity in genetic studies, using this array as a tool to foster inclusivity. GP2 is the first supported resource project of the Aligning Science Across Parkinson's (ASAP) initiative that aims to support a collaborative global effort aimed at significantly accelerating the discovery of genetic factors contributing to Parkinson's disease and atypical parkinsonism by generating genome-wide data for over 200,000 individuals in a multi-ancestry context. Here, we present the Illumina NeuroBooster array (NBA), a novel, high-throughput and cost-effective custom-designed content platform to screen for genetic variation in neurological disorders across diverse populations. The NBA contains a backbone of 1,914,934 variants (Infinium Global Diversity Array) complemented with custom content of 95,273 variants implicated in over 70 neurological conditions or traits with potential neurological complications. Furthermore, the platform includes over 10,000 tagging variants to facilitate imputation and analyses of neurodegenerative disease-related GWAS loci across diverse populations. The NBA can identify low frequency variants and accurately impute over 15 million common variants from the latest release of the TOPMed Imputation Server as of August 2023 (reference of over 300 million variants and 90,000 participants). We envisage this valuable tool will standardize genetic studies in neurological disorders across different ancestral groups, allowing researchers to perform genetic research inclusively and at a global scale.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Genotyping, Global Parkinson’s Genetics Program, NeuroBooster array, diversity, genetic screening, neurological diseases |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 09 Jan 2024 10:41 |
| Last Modified: | 17 Mar 2024 19:01 |
| DOI: | 10.1101/2023.11.06.23298176 |
| Open Access URL: | https://pubmed.ncbi.nlm.nih.gov/37986980/ |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3177767 |
Dimensions
Dimensions
